Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for enGene Holdings Inc. (ENGN : NSDQ)

• Company Description    enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL. Number of Employees: 57

• Price / Volume Information    Yesterday's Closing Price: $6.06 Daily Weekly Monthly 20 Day Moving Average: 283,228 shares Shares Outstanding: 51.19 (millions) Market Capitalization: $310.22 (millions) Beta: -0.27 52 Week High: $9.65 52 Week Low: $2.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.77% -29.66% 12 Week 64.67% 57.85% Year To Date -8.87% -20.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4868 RUE LEVY SUITE 220 - SAINT-LAURENT,A8 H4R 2P1 CAN ph: 514-332-4888 fax: - investors@engene.com https://engene.com

• General Corporate Information    Officers Ronald H. W. Cooper - Chief Executive Officer Ryan Daws - Chief Financial Officer Jasper Bos - Director Gerald Brunk - Director Dr. Richard Glickman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29286M105 SIC: 2836 Fiscal Year Fiscal Year End: October Last Reported Quarter: 07/01/25 Next Expected EPS Date: 12/18/25 Share - Related Items Shares Outstanding: 51.19 Most Recent Split Date: (:1) Beta: -0.27 Market Capitalization: $310.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/18/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -78.12% vs. Previous Quarter: -11.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 10/31/25 - - 07/31/25 - -39.86 04/30/25 - -32.60 ROA 10/31/25 - - 07/31/25 - -34.15 04/30/25 - -28.26 Current Ratio 10/31/25 - - 07/31/25 - 10.34 04/30/25 - 12.66 Quick Ratio 10/31/25 - - 07/31/25 - 10.34 04/30/25 - 12.66 Operating Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Net Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Pre-Tax Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Book Value 10/31/25 - - 07/31/25 - 3.93 04/30/25 - 4.45 Inventory Turnover 10/31/25 - - 07/31/25 - - 04/30/25 - - Debt-to-Equity 10/31/25 - - 07/31/25 - 0.09 04/30/25 - 0.09 Debt-to-Capital 10/31/25 - - 07/31/25 - 8.11 04/30/25 - 8.10

Powered by Zacks Investment Research ©